# Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine

> **NCT00158795** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 454 (actual)

## Conditions studied

- Haemophilus Influenzae Type b Disease

## Interventions

- **BIOLOGICAL:** Haemophilus Influenza type b vaccine

## Key facts

- **NCT ID:** NCT00158795
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00158795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00158795, "Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00158795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*